HOME >> BIOLOGY >> NEWS
AVELOX as effective as multi-dose combination therapy for intra-abdominal infections

Schering-Plough Corporation (NYSE: SGP) today reported that monotherapy with the once-daily, broad-spectrum antibiotic AVELOX (moxifloxacin HCl) was as effective and well tolerated as a standard multi-dose combination antibiotic regimen in the treatment of patients with complicated intra-abdominal infections (cIAI), according to results of a study involving 681 patients published in the current issue of the Annals of Surgery.(1) AVELOX, the only marketed fluoroquinolone antibiotic approved by the U.S. Food and Drug Administration (FDA) as monotherapy to treat cIAI, was shown to be effective at eradicating the most common bacteria that cause cIAI, including E. coli and B. fragilis.

In the study, patients who took 400 mg once daily of AVELOX intravenous (I.V.) followed by oral monotherapy achieved similar clinical cure rates (80 percent) at the test-of-cure visit (the primary efficacy endpoint) as patients who took a standard regimen of I.V. piperacillin-tazobactam followed by oral amoxicillin-clavulanate (78 percent).

Importantly, AVELOX demonstrated a significantly higher cure rate of 82 percent compared to 55 percent for the combination therapy among patients who acquired their cIAI in a hospital setting (including both mild-to-moderate and more severe hospital-acquired infections). Hospital-acquired infections are often caused by more resistant bacteria than community-acquired infections. Clinical cure rates for patients with community-acquired infections were similar between the two treatment groups.

The incidence of adverse events in the study due to any cause was similar for the two treatment groups, with the majority being mild or moderate in nature. The most common adverse events were nausea, hypokalemia, abdominal pain and constipation. The incidence of drug-related serious adverse events or premature discontinuation due to adverse events was similar for the two treatment groups.

"The results of this study are
'"/>


25-Jul-2006


Page: 1 2 3

Related biology news :

1. FDA approves AVELOX (moxifloxacin HCl) for treatment of complicated intra-abdominal infections
2. Smokeless tobacco more effective than cigarettes for delivering dangerous carcinogens into the body
3. Developing a more effective vaccine for tuberculosis
4. Cost-effective method for gene silencing is featured in Cold Spring Harbor Protocols
5. Implanon, Norplant and Jadelle are all effective contraceptives -- but side effects vary
6. High blood pressure medication strategy proves effective in Hispanic women
7. New compound effectively treats fungal infections
8. Northern forests less effective than tropical forests in reducing global warming
9. Cisplatin is more effective than carboplatin for treating nonsmall cell lung cancer
10. Scientists develop new drugs to fight colon and breast cancer more effectively
11. Avian influenza survivors antibodies effective at neutralising H5N1 strain

Post Your Comments:
(Date:11/6/2014)... metastasis, yet progress in preventing and treating migratory ... particularly challenging to design drugs that work against ... biology at Harvard Medical School. , "Unfortunately, ... metastasized." , Gujral and colleagues have now identified ... understand how metastasis begins. Their findings may also ...
(Date:11/5/2014)... associate professor of biology in the UTSA College ... the nation selected to receive a two-year $300,00 ... Exploratory Research (EAGER). The funding supports President Obama,s ... to create new technology that will demystify complex ... behaviors in neuroscience are broken into the interactions ...
(Date:11/4/2014)... LAKE CITY, Nov. 5, 2014 – University of Utah ... enzymes to help jet fuel produce electricity without needing ... be used to power portable electronics, off-grid power and ... online today in the American Chemical Society journal ... electricity through a chemical reaction between a fuel and ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Jet-fueled electricity at room temperature 2
(Date:11/21/2014)... CA (PRWEB) November 21, 2014 Why ... that makes Albert Einstein so instantly recognizable? Why have ... physicist, mathematician, astronomer and author Hilton Ratcliffe seeks out ... have nothing at all to do with science. In ... Harbor Publishing , November 21, 2014), Ratcliffe puts it ...
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014 /PRNewswire/ ... patient has been dosed in its Phase 1 ... and cisplatin for the treatment of malignant pleural ...  Polaris Group is conducting clinical trials on ADI-PEG ... other agents, for the treatment of several other ...
(Date:11/21/2014)... 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... ended September 30, 2014.  Biorem,s complete 2014 third quarter financial statements ... Financial Summary:Three-months ended September 30, , Nine-months ended ... , 2014 , 2013 , ... 5,281 , 6,715 , 14,476 Gross ...
(Date:11/18/2014)... LA (PRWEB) November 17, 2014 ... build-to-order, open architecture blade-based and rackmount computing infrastructure, ... Tesla® K80 dual-GPU accelerator throughout its GPU-enabled blade ... pair of the company’s latest proprietary 80-lane Gen3 ... eight discrete NVIDIA Tesla K80 dual-GPU accelerator cards ...
Breaking Biology Technology:“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3
Cached News: